Vivos Therapeutics (VVOS) Assets (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Assets data on file, last reported at $25.0 million in Q1 2026.

• Quarterly Assets rose 121.97% year-over-year to $25.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.0 million (up 121.97% YoY) and the FY2025 annual result came in at $25.2 million, up 64.56% from the prior year.
• Assets was little changed at $25.0 million in Q1 2026 per VVOS's latest filing, from $25.2 million in the prior quarter.
• Across five years, Assets topped out at $29.6 million in Q1 2022 and bottomed at $10.3 million in Q3 2023.
• The 5-year median for Assets is $15.8 million (2024), against an average of $18.2 million.
• The widest annual swing landed in 2022, when Assets tumbled 59.27%; it then soared 121.97% in 2026.
• Tracing VVOS's Assets over 5 years: stood at $13.7 million in 2022, then slipped by 21.79% to $10.7 million in 2023, then surged by 42.44% to $15.3 million in 2024, then soared by 64.56% to $25.2 million in 2025, then slipped by 0.43% to $25.0 million in 2026.
• Per Business Quant, the three latest VVOS Assets figures stand at $25.0 million (Q1 2026), $25.2 million (Q4 2025), and $25.6 million (Q3 2025).

Peer Comparison